By her seventies, the window to make a real difference has largely passed.
For decades, medicine has measured cardiovascular danger by the familiar landmarks — cholesterol, blood pressure, diabetes — yet half of all heart attacks and strokes arrive without warning in people who clear every one of those checkpoints. A thirty-year study from Mass General Brigham now offers an explanation, at least for women: chronic low-grade inflammation, measured through a blood marker called hsCRP, quietly raises lifetime heart disease risk by as much as 77 percent in women who otherwise appear perfectly healthy. The finding challenges not just a clinical assumption but a deeper human habit of trusting the absence of obvious signs as proof of safety — and it suggests that the window for meaningful prevention opens in a woman's forties, long before the body announces its distress.
- Half of all heart attacks and strokes strike people with none of the risk factors medicine has trained itself to watch for, leaving a vast population effectively unguarded.
- A 30-year study of over 12,000 women reveals that elevated inflammation — invisible to standard screening algorithms — raises coronary heart disease risk by 77 percent and stroke risk by 39 percent in otherwise healthy patients.
- Researchers have named this overlooked group 'SMuRF-Less but Inflamed,' and warn that current clinical equations are simply not designed to find them before a cardiac event occurs.
- A separate randomized trial found that statin therapy — cheap, well-established, and already widely used — cuts heart attack and stroke risk by 38 percent in this population, suggesting the tools to act already exist.
- Scientists are now pushing for routine inflammation screening in women starting at age 40, arguing that waiting until symptoms emerge means the opportunity to change outcomes has already passed.
Half of all heart attacks and strokes happen to people who, by every standard measure, should be fine — no high blood pressure, no elevated cholesterol, no diabetes, no smoking. They pass their screenings. Their doctors have little reason to worry. And then something goes wrong anyway.
A new study from Mass General Brigham spent thirty years trying to understand why. Drawing on data from the Women's Health Study, researchers tracked 12,530 women with none of the classic cardiovascular risk factors, measuring instead a blood marker called hsCRP, which signals chronic low-grade inflammation. The findings were striking: women with elevated hsCRP faced a 77 percent higher lifetime risk of coronary heart disease, a 39 percent higher risk of stroke, and a 52 percent greater chance of any major cardiovascular event — all while appearing perfectly healthy on paper.
The implications cut against how cardiovascular risk is currently assessed. Standard clinical tools are built around the classic risk factors these women didn't have, making them effectively invisible to the algorithms doctors rely on daily. Preventive cardiologist Paul Ridker described the gap plainly: women suffering heart attacks without standard risk factors are simply not being caught by the equations in current use, and the time to act is in their forties — not their seventies, when disease has already taken hold.
The study also pointed toward a solution. A separate randomized trial found that statin therapy reduced heart attack and stroke risk by 38 percent in this inflamed but otherwise low-risk group. Statins are not new — they have been in widespread use since the 1980s and can cost as little as two pence per tablet — but their anti-inflammatory effects may matter as much as their cholesterol-lowering properties in this population. What is new is the argument that women in their forties with elevated hsCRP but no other red flags should now be considered candidates for early treatment.
Researchers are pressing for inflammation screening to become routine in women's health assessments starting in middle age. With stroke claiming around 38,000 lives annually in the UK and nearly 137,000 in the US, the stakes are considerable. Whether clinical guidelines will be updated to reflect three decades of data — and how quickly — remains an open question.
Half of all heart attacks and strokes happen to people who, by every standard measure, should be fine. No smoking, no high blood pressure, no elevated cholesterol, no diabetes. They pass the usual screenings. Their doctors have no particular reason to worry. And then something goes wrong anyway.
A new study from Mass General Brigham has spent thirty years trying to understand why — and the answer, at least for women, points squarely at inflammation.
Researchers drew on data from the Women's Health Study, tracking 12,530 women who had none of the classic cardiovascular risk factors. What they measured instead was a blood marker called hsCRP, which signals chronic low-grade inflammation in the body. The results were striking. Women with elevated hsCRP levels faced a 77 percent higher lifetime risk of coronary heart disease compared to women whose inflammation was low. Their risk of stroke was 39 percent higher. Their odds of suffering any major cardiovascular event — heart attack, stroke, or related crisis — were 52 percent greater. All of this in women who, on paper, looked perfectly healthy.
The implications cut against the way cardiovascular risk is currently assessed. Standard screening tools used in clinical practice are built around those classic modifiable factors — the ones these women didn't have. That means a whole category of patients, the ones researchers are now calling 'SMuRF-Less but Inflamed,' are effectively invisible to the algorithms doctors rely on every day.
Paul Ridker, a preventive cardiologist at Mass General Brigham's Heart and Vascular Institute, put it plainly: women who suffer heart attacks and strokes without any of the standard risk factors are simply not being caught by the equations in current use. The data, he said, clearly show that apparently healthy women who carry elevated inflammation are at substantial lifetime risk — and the window to do something about it is in their forties, not their seventies, when the disease has already taken hold.
The study didn't just identify the problem. A separate randomized trial looked at what happens when these inflamed, otherwise low-risk patients are treated with statin therapy. The result was a 38 percent reduction in heart attack and stroke risk. Statins are typically understood as cholesterol drugs — they work by reducing the liver's production of LDL, the so-called bad cholesterol — but their anti-inflammatory effects have long been noted by researchers. The suggestion here is that their benefit in this population may run deeper than cholesterol management alone.
The drugs themselves are not new, and they are not expensive. Statins have been in widespread use since the 1980s and can cost as little as two pence per tablet. Decades of large-scale trials have established their effectiveness at reducing cardiovascular events. What is new is the argument that they should be considered for a group of women who would not currently qualify for them under standard risk guidelines — women in their forties who show elevated hsCRP but no other red flags.
Ridker's position is that waiting is the wrong strategy. Identifying these women early, before the disease has had decades to develop, is when preventive care can actually change outcomes. By the time a woman in this category reaches her seventies and has her first cardiac event, the opportunity to intervene meaningfully has largely passed.
The broader context matters here. Stroke kills around 38,000 people in the United Kingdom every year, making it the country's fourth-leading cause of death. In the United States, more than 795,000 people suffer a stroke annually, and roughly 137,000 of them die. Inflammation as a driver of chronic disease is not a new idea — it is implicated in conditions ranging from fatty liver disease to dementia — but its role as an independent cardiovascular risk factor in otherwise healthy women has not been well integrated into clinical practice.
The researchers are now pressing for inflammation screening to become a routine part of women's health assessments starting in middle age. Whether that translates into updated clinical guidelines, and how quickly, remains to be seen — but the data behind the push is now three decades deep.
Notable Quotes
Apparently healthy women who are inflamed are at substantial lifetime risk — and we should be identifying them in their 40s, not waiting for the disease to establish itself in their 70s when it is often too late.— Paul Ridker, MD, preventive cardiologist, Mass General Brigham Heart and Vascular Institute
The Hearth Conversation Another angle on the story
So the basic claim is that half of heart attacks happen to people who look healthy by every standard measure?
That's the starting point, yes. The standard checklist — smoking, blood pressure, cholesterol, diabetes — misses a significant portion of the people who end up having cardiac events.
And inflammation is what's being missed?
Specifically a marker called hsCRP, which you can measure with a blood test. It signals chronic low-grade inflammation, and in this study it turned out to be a powerful predictor of risk even when everything else looked normal.
Why women specifically? Is this only a female problem?
The study focused on women because there's a documented pattern of healthy women suffering heart attacks and strokes that current screening tools fail to anticipate. The researchers wanted to understand that gap. The inflammation finding may well apply more broadly, but this data is specific to women.
What's the argument for starting statins at forty rather than waiting?
The disease doesn't announce itself. By the time a woman has her first cardiac event in her seventies, the arterial damage has been accumulating for decades. The argument is that forty is when you can still get ahead of it.
Statins are cholesterol drugs, though. If these women don't have high cholesterol, why would statins help?
That's the interesting part. Statins do lower LDL, but they also have anti-inflammatory effects. The researchers think that second mechanism may be doing a lot of the work in this population — a 38 percent risk reduction is not a small number.
Is there any resistance to this idea in the medical community?
The source doesn't get into that directly, but changing screening guidelines is always a slow process. The researchers are essentially asking doctors to add a blood test and reconsider who qualifies for preventive medication. That's not nothing.
What would actually have to change for this to reach patients?
Updated clinical guidelines, broader awareness of hsCRP testing, and a willingness to prescribe statins to women who don't fit the current risk profile. The science is there. The institutional machinery takes longer.